Abstract
Clozapine is an atypical antipsychotic medication that has been shown to bemore effective in the treatment of refractory schizophrenia and the reduction of suicidal behavior in individuals with schizophrenia and schizoaffective disorder than other antipsychotics. Because of the 0.38% annual risk of agranulocytosis associated with clozapine use, prescription requires enrollment in a national registry with submission of complete blood count results before the medication is dispensed. Standard protocols require clozapine discontinuation or increased monitoring or both if absolute neutrophil counts (ANC) go below certain thresholds. Concerns about prolonged clozapine-induced neutropenia arise when patients require chemotherapy for the treatment of malignancy, which frequently induces a predictable but temporary period of neutropenia. We present the case of a patient being treated with clozapine who was diagnosed with lung cancer and who, in collaboration with his psychiatrist and oncologist, decided to continue clozapine during treatment with myelosuppressive chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.